×
Inhibikase Therapeutics SG&A Expenses 2019-2024 | IKT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Inhibikase Therapeutics sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
Inhibikase Therapeutics SG&A Expenses 2019-2024 | IKT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Inhibikase Therapeutics sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$87.5B
Takeda Pharmaceutical (TAK)
$47.5B
Merck (MKGAF)
$24.4B
Astellas Pharma (ALPMY)
$22B
Sandoz Group AG (SDZNY)
$17.6B
Summit Therapeutics (SMMT)
$16.8B
United Therapeutics (UTHR)
$15.6B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.2B
Catalent (CTLT)
$10.9B
Revolution Medicines (RVMD)
$7.7B
Orion OYJ (ORINY)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$4.3B
Corcept Therapeutics (CORT)
$4.3B
Dyne Therapeutics (DYN)
$3.7B
PTC Therapeutics (PTCT)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Soleno Therapeutics (SLNO)
$2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Xencor (XNCR)
$1.7B
Harrow (HROW)
$1.6B
Cassava Sciences (SAVA)
$1.5B